Less than two months after scoring what analysts deemed a "best-case" FDA approval for its cardiomyopathy drug Attruby, California’s BridgeBio is stepping into the spotlight of the J.P. Morgan ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback